66909-29-3

Basic information

• Product Name: 6-Chloro-5-methylpyridine-3-carboxylic acid
• Synonyms: 6-Chloro-5-methylpyridine-3-carboxylic acid;6-Chloro-5-methylnicotinic acid;6-Chloro-5-methylpyridine-3-carboxylic acid, 5-Carboxy-2-chloro-3-methylpyridine;5-Carboxy-2-chloro-3-methylpyridine
• CAS NO: 66909-29-3
• Molecular Formula: C₇H₆ClNO₂
• Molecular Weight: 172
• Mol File: 66909-29-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 6-Chloro-5-methylpyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-5-methylpyridine-3-carboxylic acid(66909-29-3)
• EPA Substance Registry System: 6-Chloro-5-methylpyridine-3-carboxylic acid(66909-29-3)

Safety Data

• Hazardous Substances Data: 66909-29-3(Hazardous Substances Data)

Usage

Description

6-Chloro-5-methylpyridine-3-carboxylic acid is an organic compound characterized by its chlorinated and methylated pyridine ring structure, featuring a carboxylic acid functional group. This molecule is known for its potential applications in the pharmaceutical and chemical industries due to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
6-Chloro-5-methylpyridine-3-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its ability to be further functionalized and modified makes it a versatile building block for drug development.
Used in the Treatment of ROR-γ-Mediated Diseases:
6-Chloro-5-methylpyridine-3-carboxylic acid is used as a ROR-γ (Retinoic Acid Receptor-Related Orphan Receptor Gamma) inhibitor for the treatment of ROR-γ-mediated diseases. By targeting and inhibiting the ROR-γ receptor, this compound can potentially modulate immune responses and treat conditions such as autoimmune disorders, inflammatory diseases, and certain types of cancer.

Upstream product

• 176433-43-5 6-chloro-5-methylpyridine-3-carboxaldehyde 
• 59782-89-7 2-Chloro-5-iodo-3-methylpyridine 
• 124-38-9 carbon dioxide 
• 4403-61-6 2-methyl-2-butene nitrile 
• 30574-97-1 tiglonitrile 

Downstream Products

• 942511-70-8 6-chloro-5-methylnicotinic acid ethyl ester 
• 1122090-20-3 6-(Isopropylamino)-5-methylnicotinic acid 
• 1186617-39-9 5-methyl-6-pyrrolidin-1-yl-nicotinic acid 
• 1186618-27-8 C₂₄H₃₁N₅O₃ 
• 1186617-62-8 2-ethyl-6-methyl-4-[5-(5-methyl-6-pyrrolidin-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-phenol 
• 1186618-30-3 N-((S)-3-{2-ethyl-6-methyl-4-[5-(5-methyl-6-pyrrolidin-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]phenoxy}-2-hydroxypropyl)-2-hydroxyacetamide 
• 1186617-59-3 N-((S)-3-{4-[5-(6-diethylamino-5-methyl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}-2-hydroxypropyl)-2-hydroxyacetamide 
• 1516901-64-6 (S)-N-(3-(2-ethyl-4-(5-(6-isopropyl-5-methylpyridin-3-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1122090-09-8 isopropyl 6-chloro-5-methylnicotinate 

Relevant articles and documents

Novel S1P1 receptor agonists - Part 3: From thiophenes to pyridines

In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P 1 agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P1 agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P 1 agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P1 and S1P3 receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.